ZOLL, ZOLL Medical Corporation

ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced that fiscal 2011 revenues were $523.7 million, compared to fiscal 2010 revenues of $444.0 million, an increase of 18%. Revenue results reflected a positive foreign exchange impact of approximately $6 million. Net income for the year grew 65% to $31.3 million, compared to $18.9 million in the prior year. Gross margins improved to 57% on the year, compared to 54% in the prior year. Diluted earnings per share grew 60% to $1.39, compared to $0.87 in the prior year. Backlog at the end of the year was approximately $30 million, as compared to $14 million at the end of the prior fiscal year. The Company ended the year with approximately $75 million in cash and short-term investments and generated approximately $45 million in cash from operations during the year.

Annual sales to the North American market increased 6% to $273.3 million, compared to $258.5 million for the prior year. Sales to the North American hospital market increased 14% to $142.6 million, compared to $125.1 million last year. Excluding U.S. Military sales, North American hospital sales increased 8% to $110.7 million from $102.4 million. U.S. Military sales were $32.0 million, compared to $22.7 million in the prior year period. Sales to the North American pre-hospital market decreased 2% to $130.7 million, compared to $133.4 million in the prior year. International revenues increased 21% to $139.3 million, compared to $114.8 million last year. Total Temperature Management revenue grew 38% to $26.0 million, compared to $18.9 million in the prior year. Total LifeVest revenues (which are excluded from geographic sales figures) increased 57% to $111.0 million compared to $70.7 million last year. Total AutoPulse sales decreased 1% to $17.3 million for the year, compared to $17.5 million in the prior year.

Commenting on the year, Richard A. Packer, Chief Executive Officer of ZOLL, stated, “2011 was a very strong year for ZOLL. Our annual revenues exceeded $520 million for the first time, making us the clear leader in the resuscitation market. We were particularly happy to outperform our bottom-line. The key revenue drivers included a strengthening of our core defibrillator business along with continued growth in both our LifeVest and Temperature Management businesses.”

ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

More about ZOLL at www.zoll.com.

Read full article at: http://pennyomega.com/18437/stock-alerts/zoll-shaw-clno-jnpr-omg-stock-highlights-by-pennyomegacom/

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

********************************



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services and 4,000,000 shares of 144 restricted stocks from the company for management fee through end of June for Cleantech Transit, Inc. (CLNO.OB).